AtriCure, Inc. ATRC

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

• GlobeNewswire Inc. 26 ago

  Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

  The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

  

• The Motley Fool 7 ago

  Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

  AtriCure director Maggie Yuen sold 3,500 shares (20% of her stake) at $38.42 per share on August 5, 2026, totaling $134,470. The sale occurred after the company reported strong Q2 results with 13% revenue growth to $154 million and expanded gross margins to 77%. The stock has surged over 60% since June lows, and analysts suggest the director sales likely reflect a post-earnings trading window opening rather than loss of confidence in the company.